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1. Introduction  
Malignant gliomas are the most common adult primary brain cancers and are amongst the 
most devastating of human malignancies. These cancers are characterized by high 
proliferation and invasion into normal brain. Treatment consists of a combination of 
surgery, radiotherapy, and chemotherapy. Despite years of experience and refinement of 
these treatments, patients suffering from World Health Organization grade four gliomas 
have a mean survival of 14 months (Stupp et al., 2005). 
The goal of surgery is to remove the entirety of the tumor as strong emerging evidence 
suggests that completeness of resection improves cancer control and lengthens survival. 
Extent of resection, for malignant gliomas, is based on gadolinium-enhanced magnetic 
resonance imaging (MRI). In cases of complete resection, radiotherapy is then delivered to a 
2 cm border along the resection cavity. In cases of incomplete resection, radiotherapy is 
delivered to the residual tumor and a 2 cm border along the residual tumor and resection 
cavity. The rational for this radiotherapy strategy is that invasive cancer cells can be found 
up to 2 cm distant from the main tumor mass.  
Studies examining the location of malignant glioma recurrence following surgery and 
adjuvant radiotherapy and chemotherapy have found that most cancers recur within a 1 cm 
border along the surgical resection cavity, even in cases in which no residual gadolinium-
enhancing tumor was evident on immediate post-operative MRI. This suggests that 
gadolinium-enhanced MRI does not sufficiently reveal the entire tumor resulting in residual 
tumor post-operatively. Other common MRI sequences, including FLAIR and T2, do not 
adequately distinguish non-gadolinium enhancing cancer cells from peritumoral edema. 
The inability to accurately visualize the whole tumor, including invasive cells, on imaging 
decreases the likelihood of complete resection. Recently, attempts to visualize malignant 
gliomas with newer imaging techniques, including metabolic labeled positron emission 
tomography (PET), have identified tumor borders beyond those seen with gadolinium-
enhanced MRI. These technologies may have profound implications regarding surgical 
planning in malignant glioma surgery. 
Historically, extent of tumor resection has been determined by the surgeon’s qualitative 
assessment at the time of operation, often reporting a gross total resection. More recently, 
the use of immediate post-operative MRI has revealed that complete resection of the 
gadolinium-enhancing portion of the tumor is achieved at a much lower rate. This 
overestimation by surgeons is, in part, owing to the difficulty distinguishing cancer cells  
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from normal brain. Since malignant gliomas are highly invasive tumors, the margin between 
tumor and normal brain is typically not obvious. Reluctant to cause an irreversible 
neurological deficit, surgeons will error on the side of caution. The downside is that 
malignant cancer cells will remain. Since adjuvant radiation and chemotherapies are only 
modestly effective (Stupp et al., 2005), these cancer cells that remain along the border of the 
original tumor mass will recur. Intraoperative tools designed to help surgeons distinguish 
cancer cells from normal brain include ultrasound and fluorescence guided surgical 
resection. Comparative studies using these tools have shown higher rates of complete 
resection compared to standard operating techniques. 
Here we review current and emerging imaging technologies designed to better visualize the 
tumor on preoperative imaging. We also review developing surgical technologies to help 
surgeons distinguish cancer cells from normal brain intraoperatively. The development of 
these technologies will lead to an increased rate of complete resection and thus improved 
cancer control. 
2. Preoperative glioma imaging 
2.1 Tumour delineation in glioma 
The accurate characterisation of tumour size and location is crucial to decisions in diagnosis, 
presurgical planning and adjuvant therapy, as well as assessment of treatment response or 
failure in patients with a glioma. The diagnostic and tumour delineation gold standard 
remains the MRI using T1 with and without gadolinium-enhancement, T2 and fluid 
attenuation inversion recovery (FLAIR) sequences. However, classical MRI sequences 
provide an indirect assessment of tumour grade by relying on tissue density, fluid content 
and blood-brain barrier breakdown patterns. Advanced MRI techniques aim to measure 
water molecule diffusion patterns (diffusion weighted imaging), cerebral blood volume 
(perfusion-weighted MRI) and metabolic tissue composition (magnetic resonance 
spectroscopy), which are more direct measures of tumour metabolism. Furthermore, PET 
using the classical metabolic tracer fluorodeoxyglucose (FDG) or novel amino acid tracers 
have been shown to provide complimentary information to MRI in presurgical planning 
and improve outcome in low and high grade gliomas. 
2.2 Conventional MRI 
Since its first clinical use in the 1980s, MRI rapidly became the imaging modality of choice in 
cerebral tumors, owing to its resolution, grey-white matter distinction and radiation sparing 
advantages over computed tomography (CT). To image glioma invasion, changes in tissue 
density, fluid content and blood brain barrier breakdown underlie the abnormalities seen on 
classical MRI sequences. Tumour delineation in low grade gliomas (LGG) is usually 
determined by the extent of hyperintense signal on a T2 sequence. Edema is usually absent 
in LGGs and should therefore not be a confounder of T2 hyperintensity. Areas of 
enhancement after gadolinium enhancement are typically not seen in LGG and are, in fact, a 
marker of anaplastic transformation. In contrast, tumour delineation in high grade gliomas 
(HGG) cannot rely on the T2 sequence, due to the often significant edema surrounding the 
lesion. The area of enhancement on the gadolinium-enhanced T1 sequence is usually used 
for pre-operative planning, post-operative extent of resection assessment and evaluation of 
progression, treatment response or recurrence. 
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The reliability of classical MRI to fully delineate the tumour has been questioned in low and 
high grade tumours. In particular, the absence of enhancement after gadolinium injection 
does not exclude the presence of high grade cancer cells. This has been shown within non-
enhancing, T2 hyperintense lesions suspected of being LGG (Kunz et al., 2011) and outside 
the enhancement perimeter in HGG (Pauleit et al., 2005). Furthermore, the effects of various 
treatments on the blood-brain barrier, at times independent of their anti-tumoural effects, 
have highlighted the need for imaging modalities more directly linked to metabolic 
tumoural activity. For example, radiation alone or combined with chemotherapy can lead to 
a regional blood-brain barrier breakdown in 20 to 50% of treated patients, leading to new or 
increase in size of exisiting areas of enhancement on gadolinium-injected T1 sequences in 
treated patients, an entity known as pseudoprogression (de Wit et al., 2004; Brandsma et al., 
2008; Taal et al., 2008; Brandsma et al., 2009). Conversely, novel anti-angiogenic treatments 
have led to the radiological concept of pseudoresponse, whereby the anti-vascular 
endothelial growth factor treatment affects vascular permeability but may not significantly 
alter tumour progression, as evidenced by continued enlargement of hyperintensity signal 
on FLAIR and rapid relapse after interruption of treatment (Norden et al., 2008; Brandsma et 
al., 2009). In order to improve preoperative glioma grading and delineation, as well as to 
improve treatment response assessment, research in glioma imaging has focused on direct 
detection of biological tumoural changes by targeting local changes in metabolite 
composition, glucose metabolism, amino acid uptake and hypoxic markers.  
2.3 Advanced MRI techniques 
The use of advanced MRI techniques has the advantage of being available in most clinical 
settings and does not require additional, and often expensive and with limited half-lives, 
radioactive tracers. MRI can currently provide information on water mobility within tissue 
(diffusion imaging), chemical composition (proton MR spectroscopy) as well as cerebral 
blood volume (CBV) and permeability (perfusion MR) (Cao et al., 2006). 
2.3.1 Diffusion imaging 
Diffusion imaging exploits the variation of micromotion properties of water protons in 
different environments. Pathological changes such as increased cellularity, necrosis, 
cytotoxic and vasogenic edema, osmolarity and active transport mechanisms affect these 
properties. These changes have an impact on  proton diffusivity and mobility, which can be 
measured by diffusion imaging (Bammer, 2003). Diffusion imaging consists of standard 
diffusion weighted imaging (DWI), apparent diffusion coefficient (ADC) map and diffusion 
tensor imaging (DTI). DTI is a measurement of diffusion along different axes and can be 
used to determine fractional anisotropy (the preferential movement of water protons in 
certain direction), from which white matter tractography can be extrapolated. 
Although DWI has established its clinical use in the diagnosis of several cerebral 
pathologies, including acute stroke (Warach et al., 1992; Adams et al., 2007) and in 
differentiating necrotic tumours from cerebral abscesses (Kim et al., 1998; Desprechins et al., 
1999), its role in glioma grading and delineation is uncertain. Kono et al. (2001) found an 
inverse relation between tumour cellularity and the ADC value in astrocytic tumours, but 
the DWI and ADC imaging values were unable to discriminate between non-enhancing 
tumour invasion and peritumoural edema. 
Early cellular changes following treatment, such as cytotoxic edema and necrosis, can be 
measured using DWI and have been shown to predict clinical efficacy (Moffat et al., 2005). 
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Indeed, in twenty glioma patients undergoing radiotherapy, chemotherapy or combined 
treatment, the percentage of tumour volume having undergone a change in ADC signal 
after three weeks of treatment (compared to a pre-treatment MRI) was compared between 
the different radiographic outcome groups after completion of treatment. These values were 
found to be significantly different between the partial response (n = 6), stable disease (n = 6) 
and progressive disease (n = 8) groups. Although survival statistics were not provided, the 
early identification of response to treatment might allow the treatment team to offer 
therapeutic alternatives to non-responders at an earlier timepoint in the course of the 
disease. 
Using measurements of mean diffusivity (MD) and fractional anisotropy (FA), DTI has a 
potential role in delineating tumour margins within white matter. A tumour infiltration 
index (TII), derived from MD and FA values, was presented as a potential tool to 
discriminate “pure” vasogenic edema from tumour infiltrated edema (Lu et al., 2004). They 
observed that peritumoural edema FA values were lower (relative to MD values) in glioma 
patients than in meningioma and metastasis patients. They hypothesized that this was due 
to concomitant white matter disruption by tumoural invasion. This suggestion was not 
confirmed pathologically in the study, and a more recent study failed to replicate this 
hypothesis (Kinoshita et al., 2010), although a positive correlation was found between the 
TII and the standard uptake value (SUV) on 11C-methionine PET imaging (a marker of 
tumour infiltration) in peritumoural hyperintense T2 areas. 
2.3.2 Perfusion MR 
Dynamic MR imaging during intravenous injection of gadolinium can be used to calculate 
regional CBV and vascular permeability with a spatial resolution similar to DWI (Cao et al., 
2006). Both CBV and vascular permeability have been shown to correlate with glioma 
histological grade, but with significant overlap between grades (Roberts et al., 2000; Law et 
al., 2004). The use of perfusion MR in delineating tumour margins or response to treatment 
has not been explored.  
2.3.3 Proton MR Spectroscopy (MRS) 
The resonance frequency of hydrogen atoms in a magnetic field varies in function of their 
chemical microenvironment (the molecule that contains them). MRS expresses these 
differences as a chemical shift. Various metabolites commonly detected in brain tissue have 
relevance in glioma imaging because they correlate with specific metabolic events. These 
include choline-containing compounds (cell membrane turnover), creatine (energy 
metabolism), lactate (hypoxia), lipids (necrosis), and n-acetyl-aspartate (neuronal cell 
integrity). 
The MRS choline peak may provide information to delineate gliomas. The choline/NAA 
ratio has been shown to correlate with the degree of tumoural invasion (tumour cell 
density)( Croteau et al., 2001), and a cutoff  choline/NAA index (CNI) of 2.5 has been 
suggested to differentiate tumour from non-tumour MRI changes in untreated patients 
(McKnight et al., 2002). However, the role of MRS in pre-operative tumour delineation is 
limited by the poor spatial resolution of the technique (0.8 to 1 cm3 voxel size). This 
limitation might eventually be resolved with development of higher resolution MRIs. 
MRS may also play a role in treatment outcome prediction. In 28 glioblastoma patients 
undergoing combined radiotherapy and chemotherapy, the volume of metabolic 
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abnormality (determined as areas of CNI > 2.5) within the tumour correlated negatively 
with survival. Another retrospective study of 26 glioblastoma patients undergoing 
radiosurgery (following previous radiation) demonstrated increased survival when more 
than 50% of the MRS tumour volume (CNI > 2) was included in the radiosurgery target 
(Chan et al., 2004). The latter finding suggests that MRS may be of benefit in defining 
radiosurgical (and perhaps conventional radiation) target volumes. 
MRS, more specifically the Cho/NAA and NAA/Cr ratios, has shown some diagnostic 
value in differentiating tumour recurrence from radiation necrosis (Rock et al., 2004; 
Weybright et al., 2005; Sundgren, 2009). However, MRS is unreliable in the common cases of 
mixed recurrent tumour and radiation change (Sundgre, 2009).  In a recent report, Zhou et 
al. (2011) observed that viable glioma could be differentiated from normal tissue and 
radiation necrosis using a novel amide proton transfer (APT) MRI technique in an irradiated 
U87MG glioma rat model. 
2.4 Positron emission tomography 
2.4.1 The choice of radioactive label 
The most common radioactive labels used in PET are 18F and 11C. Although comparative 
studies of 18F and 11C labels using the same tracer were not found, studies comparing SUVs 
of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) (Weber et al., 2000) or [18F]fluorodopa(FDOPA) 
(Becherer et al., 2003) with L-[methyl-11C]methionine (MET) in patients with intracerebral 
lesions found similar uptake values in normal brain and tumour between the two tracers. 
Therefore, the main advantage of 18F labelled tracers seems to be the longer half-life (110 
minutes) compared to 11C (20 minutes), which allows centers without on-site cyclotrons to 
perform PET studies. 
2.4.2 The choice of labelled tracer 
The most commonly used PET radioactive tracer remains FDG. However, the 
physiologically high glucose metabolism of normal brain produces a high background FDG 
uptake which decreases the signal-to-noise ratio in FDG-PET imaging, decreasing the 
detectability of low-grade or recurrent gliomas (Chen & Silverman, 2008; Klasner et al., 
2010). In the search for alternative tracers, amino acids were found to be ideal because most 
CNS tumours show high uptake of amino acids compared to normal brain tissue, which has 
much lower amino acid requirements due to its low proliferative potential. Many different 
amino acids, such as 11C-methionine (MET), 11C-leucine and 11C-tyrosine, as well as amino 
acid analogs (18F-FDOPA, 18F-FET), have been synthesized (Klasner et al., 2010). As noted 
earlier, comparative studies showed similar uptake values between the 11C-MET, 18F-FET 
and 18F-FDOPA tracers (Weber et al., 2000; Becherer et al., 2003). Other tracers, such as 18F-
fluoromisonidazole (FMISO),  specifically target hypoxic cells (Bruehlmeier et al., 2004), 
while nucleotide analogs, such as [18F]fluorothymidine (FLT), target cell proliferation.  
2.4.3 PET in tumour diagnosis and grade 
Various amino acid PET studies have demonstrated increased tracer uptake in tumours 
compared to non-tumoural lesions, but the differential diagnosis between tumour types 
could not be made (Herholz et al., 1998; Jacobs et al., 2005; Pauleit et al., 2005). An increased 
uptake of 1.5-1.6 compared to the contralateral hemisphere was suggested as a threshold for 
viable tumoural tissue (Jacobs et al., 2005). Some studies observed a significantly higher 
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uptake in HGGs compared to LGGs using 11C-MET PET32,34, whereas other groups 
identified a non-significant trend of higher tracer uptake in higher glioma grades using 18F-
FET2 and 18F-FET PET35. Fueger et al. (2010) recently demonstrated that 18F-FDOPA PET 
SUVs were significantly different between all grades in newly diagnosed gliomas, but not in 
previously treated gliomas. They calculated an SUVmax of 2.72 to discriminate between LGG 
and HGG. Furthermore, the 18F-FDOPA values correlated with Ki-67 values in pathological 
samples. Identifying metabolic “hot spots” within non-enhancing lesions was shown to 
accurately target higher grade areas in suspected LGGs (Kunz et al., 2011). As well, 
combining PET findings with gadolinium-injected images increase the diagnostic yield of 
stereotactic biopsies in HGG (Pauleit et al., 2005). 
2.4.4 PET and tumour delineation 
Tumour margins determined by conventional MRI and PET tracer uptake often yield 
different but overlapping tumour volumes. In a report of 103 consecutive cases, Pirotte et al. 
(2006) used combined FDG-PET, MET-PET and MRI to define the planned surgical resection 
in 63 LGGs and 40 HGGs. They observed that the PET-defined tumour volume 
complemented the MRI-defined tumour volume in 96% of cases. PET imaging data altered 
the planned resection volume in 80% of cases. One of two trends was usually observed: 
either the planned resection volume was increased to achieve a complete removal of the 
tumour, or the resection volume was decreased in cases where the aim was to resect only 
the metabolically active (anaplastic) portion of the tumour. In LGG, PET imaging increased 
the planned resection volume in 57% of cases and decreased it in 27% of cases. In HGG, the 
resection volume was increased in 28% and decreased in 48% of cases. Unfortunately, 
pathological data regarding tissue in areas with discordant PET/MRI findings was not 
documented. 
Importantly, in a subsequent study using the same combined PET/MRI to plan the 
resection, the same group reported an increased survival in HGG patients when a complete 
resection of the area of increased tracer uptake on PET had been achieved (mean = 32.5 vs 
17.6 months, p = 0.0001) (Pirotte et al., 2009). Complete resection of the planned 
metabolically active volume was achieved in 70% of cases. Nariai et al. (2005) observed a 
similar survival advantage in their cohort of patients with HGGs when there was no 
residual area of elevated PET uptake. 
2.4.5 PET and evaluation of response to treatment 
An important aspect of imaging follow-up during the treatment of patients with glioma is 
the early identification of response to treatment. This allows the treating team to continue 
current treatment when it is appropriate, or to offer different treatment options as early as 
possible to non-responders. PET imaging using the nucleotide tracer 18F-FLT has shown 
promise in this respect. In a group of twenty patients with recurrent glioma treated with 
bevacizumab and irinotecan, significant tracer uptake decreases in previous metabolically 
active areas at 2 weeks and 6 weeks following initiation of treatment were only observed in 
patients surviving > 12 months (Schiepers et al., 2010). 
Another important aspect of glioma treatment follow-up is the ability to differentiate 
tumour recurrence from radiation-induced changes. In a series of 45 patients, Rachinger et 
al. (2005 ) report 93% specificity and 100% sensitivity for 18F-FET PET in detecting tumour 
recurrence (compared to 93.5% specificity and 50% sensitivity for MRI). In this study, the  
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ultimate diagnosis of radiation change was determined histopathologically in only 2 of 14 
patients. Similarly, Nariai et al. (2005) found a significant difference in SUVs between 
recurrent glioma (n = 47) and radiation changes (n = 4, as defined histopathologically or by 
resolution of radiological findings) using 18F-DOPA PET. 
In summary, PET imaging provides complementary information to MRI in the diagnosis, 
tumour delineation and treatment follow-up of gliomas. Amino acid tracers are better suited 
to study brain cancers due to the greater signal to noise ratio compared to normal cerebral 
tissue. Nucleotide tracers such as FLT might be more sensitive to tumoural proliferation and 
may play an important role in the identification of treatment response and the 
discrimination of tumour recurrence from radiation-induced changes. 
3. Intraoperative tools in glioma surgery 
3.1 Extent of resection 
The usefulness of aggressive resection of malignant gliomas has not been established. Many 
studies have shown no lengthening of progression free survival or overall survival with 
aggressive resection versus limited resection. The major limitation of these studies is that 
they relied on surgeon opinion to quantify the extent of resection; using qualitative terms 
such as gross total resection, subtotal resection, debulking, and biopsy. In fact, many of the 
studies predate MRI. Since malignant gliomas are highly invasive, the distinction between 
tumor and normal brain is typically not obvious. Thus, the intraoperative impression is 
often not concordant with the actual degree of resection.  
More recent studies using early postoperative MRI, less than 48 hour postoperatively, to 
accurately quantify extent of resection have shown an advantage to aggressive resection. In 
fact, not only do patients with complete resection experience long survival, patients with 
incomplete but larger resection fair better than patients with incomplete but smaller 
resections (Stummer et al., 2006; McGirt et al., 2009). 
Based on these findings and others there is a growing consensus that the extent of resection 
should be a primary concern, even where full resection is not possible, as the degree of 
tumor resection is associated with better patient outcomes when combined with 
chemotherapy and radiotherapy (Stummer et al., 2008). However, even for experienced 
surgeons, it can be difficult to define the tumor margins, as in many cases there is no 
demarcation between tumor and normal tissue. 
3.2 Image guided surgery: Neuronavigation 
Image guided surgery refers to a technique in which a point in a patient’s space can be 
located on preoperative imaging. In neurosurgery, image guided surgery, or 
neuronavigation, refers to the ability to use a probe to locate a particular scalp, skull, or 
brain region on the preoperative MRI or computed tomography (CT) image. Advantages of 
neuronavigation include tailored craniotomy planning, and direct correlation of cortical 
anatomy with preoperative imaging. Neuronavigation is also useful in guiding the initial 
stages of resection, close to the cortical surface. Its usefulness in accurately identifying 
deeper tumor boundaries is dependent upon maintained accuracy with preoperative 
imaging. Since the preoperative imaging is static, and brain positioning is dynamic 
throughout an operation, there can be, and often is, a loss of accuracy over the course of the 
operation. Brain movement during surgery, or brain shift, can be caused by tumor removal, 
intracranial pressure reduction manoeuvres such as diuretic administration, cerebrospinal 
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fluid evacuation and gravity. Since malignant gliomas tend to be large and invade along 
deep white matter tracts, the utility of navigation to accurately locate deep tumor borders is 
limited by a loss of accuracy during the surgery.  
Wirtz et al. (2000) studied the impact of navigation in 52 patients with grade four glioma. 
Early post-operative MRI was used to quantify the extent of resection. They found that a 
complete resection was achieved in 31% of cases in which navigation was used, whereas a 
complete resection was achieved in only 18% of cases without navigation. In contrast, 
Litofsky et al. (2006) reported that in 486 patients, the use of navigation resulted in fewer 
gross total resections. Willems et al. (2006) conducted a prospective randomized study in 
which 45 patients, each harbouring a solitary contrast-enhancing intracerebral tumor, were 
randomized for surgery with or without neuronavigation. Quantification of the extent of 
resection was determined using magnetic resonance imaging. They found that the mean 
amount of residual tumor tissue was 28.9% when navigation was not used and 13.8% when 
navigation was used. The corresponding mean amounts of residual gadolinium enhancing 
tumor tissue were 29.2 and 24.4%, respectively. These differences were not significant. They 
also found that gross total resection was achieved in five patients who underwent surgery 
without navigation and in three who underwent surgery with navigation. They concluded 
that there is no rationale for the routine use of neuronavigation to improve the extent of 
tumor resection. 
Although a consensus has not been reached, most neurosurgeons agree that 
neuronavigation is valuable in surgical planning and the early stages of resection and that 
its accuracy is dependent on the dynamics of brain positioning throughout the operation. 
Developing techniques to update the navigation system during the operation, accounting 
for brain shift, will be increase the utility of navigation in glioma surgery.  
3.3 Intraoperative MRI 
Although not actually used as a guidance tool during the time of surgical resection, 
intraoperative MRI (iMRI) can be considered a tool to increase the extent of resection since it 
is performed within the same operative setting. Typically, the surgery is taken to the point 
at which the surgeon believes the resection has been completed. The dura and skin are then 
closed in a temporary fashion and the patient is then transferred into the adjacent iMRI or 
the iMRI is brought to the patient. Upon imaging, the decision is then made if residual 
resectable tumor remains, and if so, the skin and dura are reopened and the resection 
completed. 
Advantages of this technique are that the image quality is excellent, neurosurgeons are 
familiar with this mode of imaging, and residual tumor is readily identifiable. 
Disadvantages of iMRI include the significant upfront infrastructure costs and additional 
surgical time required. Hirschberg et al. (2005) reported that the average operating time 
using iMRI was 5.1 hours and was significantly longer than in the conventional OR (3.4 
hours). Importantly, iMRI is not an online technique, it does not guide the surgery or help to 
distinguish tumor from normal brain, it is used to evaluate the extent of resection at a 
surgeon defined time point.  
Over the last 10 years, many centres have acquired, used, and are now reporting their 
experience with iMRI. Senft et al. (2010) reported their experience in using an iMRI system 
in glioma surgery. Between July 2004 and May 2009, a total of 103 patients harbouring 
gliomas underwent tumor resection with the use of a mobile low field iMRI. All patients 
underwent early postoperative high field MRI to determine the extent of resection. They  
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found that all tumors could be reliably visualized on intraoperative imaging. Intraoperative 
imaging revealed residual tumor tissue in 51 patients (49.5%), leading to further tumor 
resection in 31 patients (30.1%). Importantly, extended resection did not translate into a 
higher rate of neurological deficits. When analyzing survival of patients with glioblastoma, 
patients undergoing complete tumor resection did significantly better than patients with 
residual tumor (50% survival rate at 57.8 weeks vs. 33.8 weeks, log rank test p=0.003). 
Hatiboglu et al. (2009) studied the impact of iMRI on the decision to proceed with additional 
glioma resection during surgery and to maximize extent of resection. Patients who 
underwent craniotomy for glioma resection with high-field iMRI guidance were 
prospectively evaluated over a 1 year period. Volumetric analysis and extent of resection 
were assessed with iMRI, using gadolinium enhanced T1-weighted images for tumors 
showing contrast enhancement and T2-weighted images or nonenhancing tumors. Surgery 
was terminated after iMRI in 23 patients (52%) because gross total resection was achieved or 
because of residual tumor infiltration in an eloquent brain region. Twenty-one patients 
(47%) underwent additional resection of residual tumor after iMRI. For enhancing gliomas, 
the median extent of resection increased significantly from 84% (range, 59%-97%) to 99% 
(range, 85%-100%) with additional tumor removal after iMRI (P < 0.001). Gross total 
resection was achieved after additional tumor removal after iMRI in 15 of 21 patients (71%). 
Overall, 29 patients (65%) experienced gross total resection, and in 15 (52%), this was 
achieved with the contribution of iMRI. 
To examine whether iMRI combined with neuronavigation contributes to a significantly 
improved extent of resection in glioma surgery Kuhnt et al. (2011) analysed 293 glioma 
patients who underwent craniotomy and tumor resection with the aid of 1.5 T iMRI and 
integrated multimodal navigation. In cases of remnant tumor, an update of navigation was 
performed with intraoperative images. Tumor volume was quantified pre- and intra-
operatively by segmentation of T2-abnormality in low-grade and contrast enhancement in 
high-grade gliomas. They found that in 25.9% of all cases examined, additional tumor mass 
was removed as a result of the information provided by iMRI. This led to complete tumor 
resection in 20 cases, increasing the rate of gross-total removal from 31.7% to 38.6%. In 56 
patients, additional but incomplete resection was performed due to close location to 
eloquent brain areas.  
Leuthardt et al. (2011) recently reported their experience with the combination of awake 
craniotomy and iMRI for resection of gliomas in close proximity to eloquent cortex. They 
studied 12 patients undergoing this procedure. They found that the extent of resection was 
limited because of proximity to eloquent areas in 5 cases: language areas in 3 patients and 
motor areas in 2 patients. Additional tumor was identified and resected after iMRI in 6 
cases. Average operating room time was 7.9 hours (range 5.9 - 9.7). They concluded that 
awake craniotomy and iMRI can be safely performed to maximize resection of tumours near 
eloquent language areas. 
In summary, many centres have now reported significant improvements in extent of 
resection, without increased rates of neurologic deficit, using iMRI in glioma surgery. Most 
importantly, this surgical improvement has lead to longer survival. 
3.4 Ultrasound co-registered with MRI 
The first reports of the use of intraoperative brain ultrasonography (US) to image the brain 
were published well over 50 years ago (French et al., 1950; Ballantine et al., 1950; Balantine et 
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al., 1950). Reports using real-time B-mode 2D US imaging, as we know it today, were 
published in the early 80s (Voorhies & Patterson, 1980; Rubin et al., 1980). 2D US can be used 
at the beginning of the operation, while on dura, to image the tumor and its relationship to 
brain structures including ventricles, blood vessels, gyri, sulci and rigid structures such as the 
falx and tentorium. Such imaging, prior to dural opening, is similar to the preoperative MRI 
since tumor resection has not yet taken place and brain shift is minimal. US can also be used 
on the surface of the brain or within the resection cavity provided an adequate probe-fluid 
interface can be maintained. US is useful as an intraoperative imaging tool since it can be 
used throughout the operation to update the surgeon with respect to residual tumor and help 
identify the surgical location. Imaging in real-time compensates for the problem of brain shift 
which compromises neuronavigation techniques since they are based on the static 
preoperative images. A major drawback of 2D US is that the real-time images are displayed 
in a plane corresponding to probe positioning and not the conventional axial, sagittal and 
coronal planes commonly used by neurosurgeons. Such arbitrary orientation can be 
confusing and unsettling for many neurosurgeons.   
To address this issue, tracked US or 3D US was developed. In this technique, the US probe is 
registered to the neuronavigation system and the 2D images are acquired and reformatted into 
3D. These images can then be displayed with the corresponding MR images to better orient the 
user, an attractive solution for most neurosurgeons. To assess the usefulness of 3D US in 
detected tumor, Unsgaard et al. (2005) compared 3D ultrasound with preoperative MR images 
in 28 tumor cases and found that ultrasound was at least as good as MRI in identifying tumor 
borders. Other studies have also validated the accuracy of US in brain tumor surgery. 
Gerganov et al. (2008) compared 3D US reconstructions with iMRI during brain tumor 
resection procedures and found that the image quality before the resection to be of similar 
quality with both modalities. Similarly, van Velthoven et al. [23] found that ultrasound is as 
reliable as MRI to delineate gliomas, metastases and meningiomas. In fact, it may even be 
superior to MRI in defining low-grade tumor boundaries (Unsgaard et al., 2005).  
Three dimensional US may be useful in identifying tumor, but does its lead to an increased 
extent of resection? To answer this question, Unsgaard et al. (2002) reported on their series 
of cases in which the operation was taken to the point at which the impression was that no 
residual tumor remained. At this time 3D US imaging was used and revealed previously 
unidentified residual tumor was found in 53% of cases.  
More recently, 3D US has been improved to take into account brain shift during the course 
of the operation. Using a non-linear algorithm, Mercier et al. (2011 ) have shown that they 
are able to fit the US taken during and at the end of the operation with the preoperative MRI 
taking into account brain shift so as to provide the surgeon with real-time imaging 
referenced to the preoperative MRI. They found that interpreting the post-resection 
ultrasound is easier when properly registered with the preoperative MRI and with the pre-
resection ultrasound. Further studies are necessary to determine if this translates into 
increased extent of resection. 
3.5 Fluorescence guided resection 
The ability to visualize the tumor intraoperatively, and distinguish it from normal brain 
would present an ideal situation allowing for maximal resection of brain cancers. Such a 
technique would require high sensitivity and specificity. 
5-aminolevulinic acid (5-ALA) is a natural biochemical precursor of hemoglobin that elicits 
synthesis and accumulation of fluorescent porphyrins in various epithelia and cancerous 
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tissue (Mlkvy et al., 1998). The topical form of this agent is FDA approved for and has been 
employed for dermatologic surgery (Roberts & Cairnduff, 1995; Lang et al., 2001; Sadick, 
2010). 5-ALA is produced at the cytosolic surface of the mitochondrial membrane and then 
transported to the cellular cytosol for hemebiosynthesis (Kennedy et al., 1990; Kennedy & 
Potter, 1992; Henderson et al., 1995; Kloek et al., 1996). The availability of 5-ALA in the cell 
cytoplasm is the rate limiting factor in heme biosynthesis in all but erythopoetic cells. Heme 
biosynthetic enzymes are more active in brain cancer than in normal brain tissue. As a 
result, addition of ALA (the rate-limiting agent and precursor) to malignant glial cells leads 
to an increase in the intracellular accumulation of protoporphorin IX, a fluorescent 
intermediary in heme biosynthesis (Kennedy et al., 1990; Kennedy & Potter, 1992; 
Henderson et al., 1995; Kloek et al., 1996). As a result, malignant glial cells fluoresce red 
relative to normal brain tissue when visualized under ultraviolet light.  
Stummer et al. (1998) reported on the sensitivity and specificity of 5-ALA. Intraoperatively 
detected areas of weak or strong fluorescence are tumor-cell positive in the majority of cases 
[84.8% (90% CI: 70.7% - 93.8%)], and only a low number of fluorescent (all weakly) biopsies 
are tumor cell negative (3.8% of all biopsies taken). The minimum tumor cellularity of 4.5% 
is requried for 5-ALA detectable under fluorescence light. Approximately two thirds of non-
fluorescent biopsies taken from normal adjacent tissue are tumor-cell positive, 
demonstrating the invasive growth pattern of malignant glioma. 5-ALA-induced 
fluorescence detection sometimes fails to identify areas that show contrast-enhancement in 
postoperative MR, especially in those areas that are not accessible by the blue light source. 
Several European centers have investigated the role of 5-aminolevulinic acid in fluorescence 
guided resection of newly diagnosed Grade III/IV astrocytomas (Stummer et al., 1998; 
Stummer et al., 2000; Stummer et al., 2006). Stummer et al. (2006) demonstrated in their 
randomized multicenter phase III trial (n = 322 patients, dose of 20 mg/kg body weight) a 
gross total resection rate of 63.6% in the experimental arm (5-ALA guided resection) versus 
37.6% in the control arm (standard white light resection). Clinically, this translated into a 
higher 6 month progression free survival than those allocated to white light resection (41.0% 
versus 21.1%). This trial is the first study that showed prospectively that fluorescence-
guidance increases the completeness of resection of malignant gliomas. 
In the clinical studies 5-ALA has proven to be safe. Events have been classified according to 
their relationship to the drug, and those related to the combination of drug and procedure. 
During the last 2 years in the post marketing studies in Europe under a stringent risk 
management program, no significant adverse effects have been reported to regulatory 
authorities in Europe.  
In 2006 it was reported that the use of 5-ALA was associated with improved gross tumor 
resection when used as a fluorescent agent in high grade glioma (Stummer et al., 2006). This 
European registration trial for 5-ALA as a fluorescent guided probe for tumor visualization, 
revealed a marked improvement in percentage of patients achieving gross total resection 
compared to normal operating white light (64% vs 38%, p < 0.001). Randomized control 
trials in both Canada and United States of America are in the final stages of preparation. 
4. Conclusion 
Since the routine use of early post-operative MRI to accurately quantify extent of resection 
has become common, studies are now being reported revealing that increased extent of 
resection yields improvements in overall survival. However, even in cases of complete 
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resection of the MRI based gadolinium-enhancing portion of the tumor, tumors always 
recur and the prognosis is poor. 
While MRI based imaging is the current standard for tumor imaging, labelled tracer PET 
imaging is emerging as a complimentary technique to better visualize the entirety of the 
tumor. Just as it is difficult to visualize the entirety of the tumor on imaging, it is also 
difficult to visualize the tumor, and distinguish it from normal brain, intraoperatively. 
Imaging tools that can be used to increase the rate of resection include iMRI, 3D US, and 
fluorescence guided surgery.  
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